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Background. Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant
peripheral nerve sheath tumors (MPNST) has been reported.Methods. We evaluated the objective response (OR) rate of patients
with AJCC Stage III/IV chemotherapy-naive NF1 MPNST versus sporadic MPNST after 4 cycles of neoadjuvant chemotherapy, 2
cycles of ifosfamide/doxorubicin, and 2 cycles of ifosfamide/etoposide. A Simon optimal two-stage designwas used (target response
rate 40%). Results. 34 NF1 (median age 33 years) and 14 sporadic (median age 40 years) MPNST patients enrolled. Five of 28 (17.9%)
evaluable NF1 MPNST patients had a partial response (PR), as did 4 of 9 (44.4%) patients with sporadic MPNST. Stable disease
(SD) was achieved in 22 NF1 and 4 sporadic MPNST patients. In both strata, results in the initial stages met criteria for expansion
of enrollment. Only 1 additional PR was observed in the expanded NF1 stratum. Enrollment was slower than expected and the
trial closed before full accrual. Conclusions. This trial was not powered to detect differences in response rates between NF1 and
sporadic MPNST. While the OR rate was lower in NF1 compared to sporadic MPNST, qualitative responses were similar, and
disease stabilization was achieved in most patients.
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1. Introduction
Malignant peripheral nerve sheath tumors (MPNST) are soft
tissue sarcomas associated with high risk of local recurrence,
hematogenous metastasis, and high sarcoma-specific death
rate [1–4]. They account for approximately 4% of all soft
tissue sarcomas and occurmainly in adults, with only 10–20%
occurring in patients less than 20 years old [5–8]. Half of
MPNST arise in patients with neurofibromatosis type 1 (NF1),
with a lifetime incidence of 15.8% in NF1 compared to an
incidence of 0.001% in the general population [1, 9, 10]. In
NF1, MPNST occurs at a younger age and the majority arise
in preexisting plexiform neurofibromas (PNs) [11, 12].
Most patients present with a soft tissue mass that arises
from a peripheral or major nerve and may have symptoms
of pain, paresthesias, or weakness [13]. The diagnosis in
patients with NF1 can be delayed because clinical indicators
of malignancy such as mass and pain can also be features of
benign PNs. Worse 5-year overall survival has been reported
for NF1 MPNST (32%, 11%) compared to sporadic MPNST
(55%, 44.7%), though, in recent years, studies have shown this
difference is decreasing [3, 14, 15]. A French group recently
reported that in patients with MPNST NF1 status was not
negatively prognostic except in patients with recurrence or
metastasis [16].
To date, complete surgical resection with wide negative
margins is the only potentially curative treatment option for
localizedMPNST. Radiation treatment at high doses has been
recommended for tumors ≥ 5 cm and in the presence of
microscopic positive margins [17]. While the use of dose-
intensive neoadjuvant chemotherapy is standard for patients
with rhabdomyosarcoma and Ewing sarcoma, the survival
benefits of this strategy are less established for other types
of soft tissue sarcoma, though current clinical trials are
underway [18–21]. Although several small phase II trials
have reported that preoperative chemotherapy may increase
the ability to successfully perform conservative surgery, the
impact of this strategy on overall survival has not been well
prospectively addressed [22, 23]. Doxorubicin and ifosfamide
are considered the most active agents in treating soft tissue
sarcomas, and etoposide has shown some increased response
when combined with ifosfamide [24–27]. A retrospective
analysis of EORTC trials found that doxorubicin-ifosfamide
regimens are superior to other regimens and outcomes for
MPNST are similar to those of other soft tissue sarcomas [28].
Because topoisomerase II𝛼 (TOPO2A) has been reported as
the most overexpressed gene in MPNST compared to benign
neurofibromas, targeting with a topoisomerase II inhibitor
such as etoposide may be well suited for this particular type
of sarcoma [29].
There is limited knowledge of the response rate of
MPNST to standard chemotherapy agents used to treat
pediatric and adult sarcomas. Two studies reported lower
response to chemotherapy (partial response rates 8%–18%
in NF1 MPNST versus 55%–60% in sporadic MPNST) and
worse survival (5-year OS 11–32% versus 44–55%, resp.)
in NF1-associated MPNST compared to sporadic MPNST.
However, these studies were not designed prospectively and
used a variety of chemotherapy agents on different protocols
[3, 14].
The rationale for neoadjuvant therapy is severalfold,
including (1) chemotherapy induced tumor shrinkage lead-
ing to easier and less morbid resection, (2) treatment of
micrometastatic disease at diagnosis, and (3) response to
chemotherapy can be assessed in individual patients allowing
for tailoring of further treatment.The aim of this phase II trial
was to prospectively determine the imaging response (WHO
criteria) of AJCC Stage III/IV sporadic or NF1-associated
MPNST after neoadjuvant chemotherapy with 2 cycles of
ifosfamide and doxorubicin (IA), followed by 2 cycles of
ifosfamide and etoposide (IE). Patients were stratified for
NF1-associated versus sporadic MPNST to assess response in
these groups separately.
2. Methods
2.1. Study Oversight. This multi-institutional trial was spon-
sored by the United States Department of Defense (DoD),
developed by NCI investigators in collaboration with the Sar-
coma Alliance for Research through Collaboration (SARC)
and coordinated by SARC.The protocol was approved by the
local institutional review board at each participating site and
registered on ClinicalTrials.gov NCT00304083. All patients
or their legal guardians provided written informed consent
and assent (patients 13 through 17 years old).
2.2. Patient Eligibility. Children and adults (no upper or
lower age limit) with measurable, high-grade (stage III
per AJCC TNM staging system) or metastatic (stage IV)
sporadic or NF1-associated MPNST not previously treated
with chemotherapy for MPNST were eligible for the study.
Organ function requirements included a normal serum cre-
atinine for age or creatinine clearance > 60mL/min/1.73m2,
alanine aminotransferase < 5x the upper limit of normal and
bilirubin< 2.5x the upper limit of normal, absolute neutrophil
count ≥ 1500/mcL, hemoglobin ≥ 9.0 g/dL, platelet count ≥
100,000/mcL, and normal left ventricular ejection fraction on
MUGA scan or echocardiogram.
2.3. Trial Design
2.3.1. Treatment Regimen. Patients were stratified for the
presence of NF1-associated (stratum 1) or sporadic (stra-
tum 2) MPNST. NF1 clinical findings were documented
at enrollment using a standardized form. In each stratum,
patients received 2 cycles (one cycle = 21 days) of doxorubicin
and ifosfamide (IA) followed by 2 cycles of ifosfamide and
etoposide (IE) (Figure 1). Mesna, peg-filgrastim or filgrastim,
and dexrazoxane were given per institutional guidelines.
Details regarding trial design, chemotherapy dosing, and
supportive therapy are included in Supplementary Appendix
Table S1 (see Supplementary Material available online at
https://doi.org/10.1155/2017/8685638). If the start of the sec-
ond or subsequent treatment cycles was delayed for >7 days
by a nonhematologic toxicity that had not resolved to a level
that would allow for initiation of the next treatment cycle,
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Figure 1: Trial design and treatment plan.
then the dose of agents that were judged to be responsible for
the prolonged toxicity could be reduced by 25%.
Patients underwent local control (radiation and/or
surgery), if feasible, after cycle 4, followed by 2 more cycles
of IA and IE, for a planned 8 total chemotherapy cycles.
The cumulative doxorubicin, ifosfamide, and etoposide
doses were 300mg/m2, 72,000mg/m2, and 2000mg/m2,
respectively. Response was assessed using standard MRI/CT
after cycles 2, 4, 6, and 8. Patients who underwent only
surgery received 2 more cycles of IA followed by 2 more
cycles of IE. Those who underwent radiation could receive
IE during radiation followed by 2 more cycles of IA, as
doxorubicin cannot be given concurrently with radiation.
If patients developed disease progression after the first 2
cycles of IA, chemotherapy continued on protocol and they
received 2 cycles of IE. Patients who experienced disease
progression after 2 cycles each of IA and IE were permanently
removed from the trial.
2.3.2. Study Evaluations. Patients underwent regular safety
evaluations: history, physical examinations, complete blood
counts (CBC), electrolytes, liver function tests, and urinalysis
prior to all cycles; CT chest and MRI of primary site prior
to cycles 1, 3, 5, and 7; and, if possible, 18FDG-PET prior
to cycles 1 and 5. CBC, electrolytes, and liver function tests
were monitored at least weekly during treatment cycles (see
Supplementary Appendix Table S2 for details).
2.3.3. Evaluation of Toxicities. National Cancer Institute
Common Terminology Criteria for Adverse Events, version
3, were used to grade adverse events.
2.3.4. Response Criteria. WHO as opposed to RECIST cri-
teria were used to determine responses due to the non-
spherical shape of most MPNST [30, 31]. Responses were
centrally reviewed at the NCI (ED). Patients were considered
nonevaluable for response if they were removed from treat-
ment for reasons other than disease progression or toxicity
such as withdrawal of consent or noncompliance.
2.3.5. Statistical Considerations. A Simon optimal two-stage
design was used to evaluate response (complete and partial
responses) to chemotherapy (WHO criteria) in order to rule
out a 20% response rate (𝑝
0
= 0.20) and target a desirable goal
of a 40% response rate (𝑝
1
= 0.40) separately within 2 strata:
NF1-associated (stratum 1) and sporadicMPNST (stratum 2).
Response evaluation after cycle 4 was used for determination
of the primary trial endpoint. With alpha = 0.10 (probability
of accepting a poor treatment) and beta = 0.10 (probability
of rejecting a good treatment), in the first stage of each
stratum, 17 patients were to be enrolled. If 0–3 patients
responded, the regimen was to be considered inactive in that
stratum and enrollment terminated. If ≥4 patients achieved
partial response (PR) or complete response (CR), accrual
would continue until a total of 37 patients were enrolled. The
regimen would be considered active if ≥11 of 37 patients in
the expanded stratum experienced a PR or CR; this would
be consistent with a 40% response rate (the upper bound of
a one-sided 90% CI would include 40%). With this design,
the probability of early termination was 55% if the true
response rate was only 20%. Secondary endpoints were to
determine clinical phenotypes in NF1 patients with MPNST
using a standardized evaluation form at trial entry, to perform
a central, detailed, and standardized pathology evaluation
(AP), compare response evaluation by RECIST versusWHO,
and to evaluate the response of plexiform neurofibroma
(if present) to neoadjuvant chemotherapy using magnetic
resonance imaging (MRI) volumetric analysis.
2.3.6. Central Pathology Review. The MPNST diagnosis was
centrally confirmed. In addition, detailed analyses including
determination of tumor margin, histologic variant, cellular-
ity, number of mitoses, presence of tumor necrosis, grade,
immunohistochemical features (including S100, p53, and
MIB-1, a marker for cell proliferation), and fluorescence
in situ hybridization (FISH) studies were performed for
copy number alterations of 10 known tumor suppressor and
oncogenes, including TOPO2A amplification on provided
samples (see Table S3).
3. Results
3.1. Patient Characteristics. Between 9/2006 and 6/2012, 49
patients enrolled, 48 of whom were eligible. One patient was
ineligible because on central pathology review the tumor
was found to be a clear cell sarcoma. The characteristics of
the 48 eligible patients are listed in Table 1. The majority
of primary tumors were located in the trunk (𝑛 = 34,
24 NF1, 10 sporadic). Twenty-five patients had metastatic
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Table 1: Patient characteristics at enrollment and response evalua-
tion.
Stratum NF1 MPNST Sporadic MPNST
Eligible patients enrolled 34 14
Male/female 22/12 9/5
Median age: years (range) 33 (8–66) 40 (13–72)
Race: 𝑛 (%)
White, non-Hispanic 14 (41%) 11 (79%)
Black 13 (38%) 2 (14%)
Hispanic 4 (12%) 0 (0%)
Other/unknown 3 (9%) 1 (7%)
ECOG score: 0/1/2 4/24/6 6/5/3
Disease: localized/metastatic 18/16 5/9
Location
Head 2 0
Neck 3 1
Chest 10 4
Abdomen/pelvis 9 5
Spine 5 1
Upper extremity 3 1
Lower extremity 2 2
Response evaluation after cycle 4 28 9
Complete response (CR) — —
Partial response (PR) 5 4
Stable disease (SD) 20 4
Progressive disease (PD) 3 1
Objective response rate: % 17.9 44.4
disease at the time of diagnosis (16 NF1, 9 sporadic). No
patient had received prior chemotherapy or radiation therapy
for their MPNST. Of the 26 patients with NF1 who had
pathology available for review, 13 of the MPNST arose from a
plexiform neurofibroma, 5 did not, and 8 were unknown.The
majority of patients withNF1 had plexiformneurofibromas as
well as multiple cutaneous and subcutaneous neurofibromas
(Table 2).
3.2. Responses. Both initial stages met criteria for expansion
of enrollment with 4/17 partial responses in NF1 and 5/9
partial responses in sporadic MPNST after cycle 4. The
NF1 stratum went on to enroll 17 additional patients for a
total of 34 patients and the sporadic stratum enrolled an
additional 5 patients for a total of 14 patients. Enrollment
on the trial was then closed due to slow enrollment and
availability of competing clinical trials for MPNST. Overall,
37 of the 48 patients were evaluable for response (28 NF1,
9 sporadic MPNST). Patients were deemed nonevaluable for
the following reasons; PI decision (𝑛 = 2), early local control
(𝑛 = 3), patient withdrawal (𝑛 = 4), death during cycle 1
(𝑛 = 1) due to internal hemorrhage unrelated to therapy, and
noncompliance (𝑛 = 1).
In total, after cycle 4 evaluation, there were 9 patients with
partial responses (5/28-17.9% NF1 MPNST, with exact 95%
Table 2: Baseline NF1 clinical findings in 34 patients with NF1
MPNST.
NF1 diagnostic signs (number of subjects with data
provided)
6 or more CAL (𝑛 = 28) 17
Intertriginous freckling (𝑛 = 28) 19
Neurofibromas (𝑛 = 28) 26
Subcutaneous neurofibromas (𝑛 = 24)
(0/1–9/≥10) 4/10/10
Cutaneous neurofibromas (𝑛 = 24)
(0/1–9/≥10) 6/5/13
Plexiform neurofibroma (𝑛 = 20) 12
Paraspinal neurofibromas (𝑛 = 24) 12
Glioma/optic glioma (𝑛 = 18) 1/1
Other morbidity
Scoliosis (𝑛 = 22) 5
Intellectual delay (𝑛 = 26) 8
Hypertension (𝑛 = 28) 8
Confidence Interval (CI) 6.1–36.9%, and 4/9-44.4% sporadic
MPNST, with exact 95% CI 13.7–78.8%) and 24 with stable
disease (20 NF1 MPNST, 4 sporadic MPNST) and 4 patients
with PD (3 NF1 MPNST, 1 sporadic MPNST) (see Table 1 and
Figure 2, Supplementary Appendix Table S3). The objective
response rate was thus lower in NF1 (17.9%) compared to
sporadic (44.4%) MPNST. Of the 9 PR, 5 were initially
observed after 2 cycles IA and 4 additional partial responses
after completion of 2 cycles of IE. There were 4 patients with
progressive disease after IA, one of whom had regression of
tumor to SD after 2 cycles of IE. In addition to the patient
with regression to SD at the end of cycle 4, 5 patients (4 NF1,
1 sporadic) had decrease in their MPNST after cycle 4 IE
following initial growth from baseline after 2 cycles of IA.
In the NF1 stratum, the median number of treatment
cycles was 5 (range 1–8); of the 26 patients who received ≥
4 cycles, 12 completed all 8 cycles. For the sporadic stratum
the median number of cycles was 4.5 (range 1–8) and of 10
patients who received ≥ 4 cycles, 6 completed all 8 cycles.
The most frequent reasons for removal from treatment prior
to completion of all 8 cycles were PI decision (8 NF1, 3
sporadic), disease progression (5NF1, 1 sporadic), and patient
withdrawal (4 NF1, 2 sporadic).
Of 22 patients in the NF1 stratum who remained on
study after 4 cycles, 7 underwent surgery only, 5 had surgery
and radiation, 4 received radiation only, and 6 had neither
radiation nor surgery for local control. In the sporadic group,
7 patients remained on study after 4 cycles, 3 of whom
underwent surgery only, 1 had surgery and radiation, 2 had
radiation only, and 1 received neither radiation nor surgery
for local control.
The secondary endpoint, to evaluate the response of plexi-
formneurofibroma (if present) to neoadjuvant chemotherapy
using volumetric MRI analysis as a tool for response assess-
ment, could not be evaluated. Formost patients,MRI imaging
of the MPNST and plexiform neurofibroma component was
not sufficient to allow for volumetric analysis over time.
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Figure 2:Waterfall plots showing change in 2-dimensional tumormeasurements according toWHOcriteria after 4 cycles (2 cycles ifosfamide
and doxorubicin, IA, and 2 cycles of ifosfamide and etoposide, IE, upper panels) and 2 cycles (IA, lower panels). On all four panels patients
are arranged by best response measured after cycle 4. ‰Patients removed from treatment after cycle 2. jTarget lesion stable, but progressive
disease with new lesion.
Reasons for this included differences in imaging technique
over time and incomplete coverage of the entire tumor
(MPNST and preexisting plexiform neurofibroma).
For 33 patients who were evaluable for response after
cycle 4, response evaluation using WHO and RECIST was
performed. Response determination was in agreement with
exception of two patients who had stable disease by WHO
criteria (−39%, −46%) but a partial response by RECIST
criteria (−30%, −31%), one patient who had progressive
disease (52.6%) by WHO criteria and stable disease (18%) by
RECIST criteria, and one patient with stable disease (−28%)
by RECIST criteria but partial response (−54%) by WHO
criteria.
3.3. Toxicity. Eight patients had dose reductions of chemo-
therapy with three of those being for neurotoxicity associated
with ifosfamide. Serious adverse events with possible, proba-
ble, or definite relationship were reported for 9 patients with
NF1 and 4 patients with sporadic MPNST including febrile
neutropenia (𝑛 = 6), anemia (𝑛 = 4), altered mental status,
aphasia, and somnolence (𝑛 = 4) attributed to ifosfamide and
secondary acute myeloid leukemia one year after completion
of treatment in one patient with NF1 MPNST.
3.4. Central Pathology Evaluation. Diagnostic biopsies and
surgical tumor specimens obtained on this trial were sent for
centralized pathology review. Thirty-seven samples (26 NF1,
6 Sarcoma
11 sporadic) were obtained prior to therapy and 9 (6 NF1, 3
sporadic) were obtained during treatment. Consistent with
the diagnosis of high-grade MPNST, the majority of NF1 and
sporadicMPNSThad high cellularity, conventional histology,
high mitotic rate, and presence of necrosis; p53 staining was
positive in most tumors, and the proliferation index (MIB-
1) was high in most tumors (for details, see Supplementary
Appendix Table S4).There were no differences for responders
or nonresponders (patients with disease progression) based
on pathology features for NF1 and sporadic MPNST. In those
patients whowere considered evaluable after 4 cycles and had
initial tissue available for FISH testing, theTOPO2A gene was
amplified in 5 of 20 samples (NF1 𝑛 = 3, sporadic 𝑛 = 2). Only
one of these patients had partial tumor response, 3 patients
had stable disease, and one NF1 patient had progressive
disease.
4. Discussion
The overall survival of unresectable or metastatic MPNST
remains poor and thus there is a critical need for the
development of effective medical treatments. This was the
first trial to prospectively evaluate the objective response
rate in high-grade chemotherapy-naive MPNST using an
identical chemotherapy regimen and stratification for NF1
and sporadicMPNST. Responses were determined separately
for sporadic and NF1-associated MPNST, as response to
chemotherapy and outcome have been reported to be worse
for NF1-associated compared to sporadic MPNST as noted
by Ferrari et al. [3, 14]. Similar to these studies, our study
also observed a lower response rate for NF1 MPNST (17.9%)
compared to sporadic MPNST (44.4%).
However, our studywas not powered to detect a difference
in objective response rates between the two strata. This trial
enrolled patients slowly over 6 years, and we closed the study
to enrollment when it was clear that enrollment could not be
completed within an acceptable time frame.With 5/28 partial
responses in NF1 MPNST, it is unlikely that the desired 40%
OR rate (≥11/37 patients) would have been met, even with
completed accrual. This trial may have recruited slowly, as
the treatment consisted of conventional chemotherapy drugs;
that is, the agentswere not novel and are available atmost sites
where they are used for the treatment for sarcomas.While the
desired response rates were not achieved, the chemotherapy
regimen selected clearly resulted in disease stabilization and
minor decreases in the target lesions were observed in most
patients. This is in contrast to recently completed clinical
trials with targeted agents, in which most patients have
experienced rapid disease progression [32–36]. IA resulted
in disease stabilization and minor decreases in tumor size in
most patients, with additional shrinkage observed following
IE in several patients.The inclusions of etoposide forMPNST
differ from the most frequently used regimen of ifosfamide
and doxorubicin. Consideration should be given to etoposide
in conventional chemotherapy regimens for patients with
MPNST as five patients in this study had shrinkage after two
cycles of IE despite growth with IA.
Disease stabilization and small reductions in tumor size
in addition to the partial responses were seen in patients
with NF1 and sporadic MPNST and appeared similar in
magnitude (Figure 2). Thus, while the partial response rate
was lower inNF1 compared to sporadicMPNST, qualitatively,
responses were similar. This suggests that there may be a role
for chemotherapy in NF1 and sporadic MPNST and that the
combination of chemotherapy with targeted agents may be
one strategy to identify more effective agents for MPNST.
A study using cDNA microarray analysis found that
TOPO2A was the most overexpressed gene in MPNST com-
pared with benign neurofibromas. Excess copies of TOPO2A
were also seen at the DNA level in 10 of 16 cases, while
increased expression of TOPO2A protein was seen in 83% of
the tumors on a tissue microarray. The TOPO2A-expressing
tumors were also associated with poor cancer-specific sur-
vival and presence of metastases [29]. Topoisomerase II is
the primary target for several anticancer agents including
doxorubicin and etoposide; the hope was that the MPNST
being more likely to express TOPO2A would be more sen-
sitive to these chemotherapy agents. TOPO2A was assessed
by FISH and only 5/20 response-evaluable MPNST were
found to harbor gene amplification. In addition, only one
of these patients had a partial response to the treatment;
however, this is too small of a sample size to draw firm con-
clusions. Additional pathologic analyses did not shed light
on additional markers of response. This study allowed for
clinical evaluation of patients with NF1manifestations at trial
enrollment, which has not been done in previous trials. In
general, in the adult NF population the percentage of patients
with ≥10 subcutaneous neurofibromas ranges between 14
and 23% while in our study it was 41% [37]. Presence of
subcutaneous neurofibroma burden has been associated with
a greater risk for MPNST in NF1 in the past [38, 39].
Our trial compared response assessment by WHO and
RECIST which was mostly in agreement. We selected WHO
over RECIST as many MPNST are not spherical. We rec-
ommend additional comparison in future clinical trials for
MPNST to evaluate whichmethod is preferable. Another goal
of our study was to assess the utility of FDG-PET in assessing
the response to therapy. However only 25 of 48 patients had
initial PET scans and only 13 patients had follow-up PET after
cycle 5 which did not allow for a meaningful analysis.
In summary, similar to previous trials, our prospective
study described a lower objective response rate in NF1-
associated compared to sporadic MPNST. While our study
did not meet final accrual and was not powered to detect
differences in response rates between sporadic and NF1-
associatedMPNST, this chemotherapy regimen used resulted
in disease stabilization in a majority of the patients, which
is important in a highly aggressive tumor. Novel treatment
strategies for MPNST, including evaluation of the combina-
tion of cytotoxic and targeted therapies, should be consid-
ered.
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